Neuralink’s most recent primary funding round—a $650 million Series E closed in May 2025—established a post-money valuation of approximately $9.65 billion, more than doubling the prior $5 billion level from 2023 and bringing total capital raised above $1.3 billion. Secondary-market trading in early 2026 has reflected significant premiums, with implied valuations reaching $47 billion amid high bid volumes, signaling strong institutional demand driven by clinical trial expansions and FDA Breakthrough Device designations for speech and vision restoration. With no IPO announced and substantial runway from the latest raise, trader sentiment hinges on upcoming trial data releases, additional regulatory milestones, and any follow-on funding rounds before year-end, as these events typically catalyze valuation re-ratings in pre-public neurotechnology companies.
基于Polymarket数据的AI实验性摘要。这不是交易建议,也不影响该市场的结算方式。 · 更新于↑$100B
10%
↑$75B
30%
↑$60B
35%
↑$50B
68%
↑$45B
83%
↓$35B
50%
↓$32.5B
58%
↓$25B
12%
NPM Prices are published for trading days only and are updated once daily at 1:00 PM ET on the following calendar day.
If NPM has not published relevant data for all business dates in the specified period by 1:00 PM ET on January 1, 2027, this market may remain open until 11:59 PM ET on January 4, 2027. If no further data is released by that time, the market will resolve according to the data available.
If NPM ceases publishing relevant data prior to the end of the specified period, this market will resolve based on the NPM data published for the period prior to the cessation of coverage, as well as any applicable public market capitalization data following an IPO or direct listing.
If the company completes an IPO or direct listing before the end of the specified period, this market will consider, in addition to the relevant NPM valuations published between market creation and the IPO or direct listing date, the valuation implied by the official IPO or direct listing price, and the company's public market capitalization between the IPO or direct listing date and the end of the specified period.
Public market capitalization will be determined using the highest/lowest official regular-hours trading price published for the company's primary listed common equity on its primary exchange for any trading day during the specified period, multiplied by the company's total outstanding common shares at the relevant time.
If the listed company merges with or acquires another entity and remains the parent company, no change to resolution methodology applies.
If the listed company is acquired, merges into another entity and is no longer the surviving parent company, or otherwise ceases to exist as an independent entity prior to the end of the period, only NPM valuations and applicable public market capitalizations achieved prior to completion of the transaction will be considered for resolution. No transaction, acquisition, or merger consideration will be considered for resolution.
The resolution source for this market is NPM data published here (https://fe.secondmarket.com/companies/company-782c0a32-4727-4097-a40b-9a2602f243e7/data). The resolution source for any period following an IPO, direct listing, or relevant corporate action, will be official exchange trading data and publicly reported share counts.
Revisions to previously published NPM data made after their initial release will not be considered, unless made to correct clearly erroneous data.
市场开放时间: May 19, 2026, 1:02 AM ET
Resolver
0x65070BE91...NPM Prices are published for trading days only and are updated once daily at 1:00 PM ET on the following calendar day.
If NPM has not published relevant data for all business dates in the specified period by 1:00 PM ET on January 1, 2027, this market may remain open until 11:59 PM ET on January 4, 2027. If no further data is released by that time, the market will resolve according to the data available.
If NPM ceases publishing relevant data prior to the end of the specified period, this market will resolve based on the NPM data published for the period prior to the cessation of coverage, as well as any applicable public market capitalization data following an IPO or direct listing.
If the company completes an IPO or direct listing before the end of the specified period, this market will consider, in addition to the relevant NPM valuations published between market creation and the IPO or direct listing date, the valuation implied by the official IPO or direct listing price, and the company's public market capitalization between the IPO or direct listing date and the end of the specified period.
Public market capitalization will be determined using the highest/lowest official regular-hours trading price published for the company's primary listed common equity on its primary exchange for any trading day during the specified period, multiplied by the company's total outstanding common shares at the relevant time.
If the listed company merges with or acquires another entity and remains the parent company, no change to resolution methodology applies.
If the listed company is acquired, merges into another entity and is no longer the surviving parent company, or otherwise ceases to exist as an independent entity prior to the end of the period, only NPM valuations and applicable public market capitalizations achieved prior to completion of the transaction will be considered for resolution. No transaction, acquisition, or merger consideration will be considered for resolution.
The resolution source for this market is NPM data published here (https://fe.secondmarket.com/companies/company-782c0a32-4727-4097-a40b-9a2602f243e7/data). The resolution source for any period following an IPO, direct listing, or relevant corporate action, will be official exchange trading data and publicly reported share counts.
Revisions to previously published NPM data made after their initial release will not be considered, unless made to correct clearly erroneous data.
Resolver
0x65070BE91...Neuralink’s most recent primary funding round—a $650 million Series E closed in May 2025—established a post-money valuation of approximately $9.65 billion, more than doubling the prior $5 billion level from 2023 and bringing total capital raised above $1.3 billion. Secondary-market trading in early 2026 has reflected significant premiums, with implied valuations reaching $47 billion amid high bid volumes, signaling strong institutional demand driven by clinical trial expansions and FDA Breakthrough Device designations for speech and vision restoration. With no IPO announced and substantial runway from the latest raise, trader sentiment hinges on upcoming trial data releases, additional regulatory milestones, and any follow-on funding rounds before year-end, as these events typically catalyze valuation re-ratings in pre-public neurotechnology companies.
基于Polymarket数据的AI实验性摘要。这不是交易建议,也不影响该市场的结算方式。 · 更新于

警惕外部链接哦。
警惕外部链接哦。
常见问题